<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Böhm, Michael</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">EASD/ESC Symposium: Renal Denervation</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">32-33</style></pages><abstract><style  face="normal" font="default" size="100%">Hypertensive individuals, who cannot achieve target blood pressure (BP) levels despite being treated with triple-drug regimens, including a diuretic, are diagnosed as having resistant hypertension (rHT) [Calhoun DA et al. Circulation 2008], which is an increasingly common clinical problem [Egan BM et al. Circulation 2011]. Renal sympathetic hyperactivity is influential in the maintenance and progression of hypertension, while the interruption of sympathetic nerves in the kidney has a strong impact on BP and survival. This article discusses the impact of renal denervation as a treatment for hypertension.</style></abstract><number><style face="normal" font="default" size="100%">16</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>